YOLFTbeta
01

GeneOne Life Science Inc

011000 · KO · Healthcare / Biotechnology

2,670.00KRW+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close2,670.00
Open2,670.00
Day Range2,670.00 – 2,670.00
52-Week Range2,600.00 – 12,450.00
Volume0
Market Cap9.71B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.72
50-Day Avg2,670.00
200-Day Avg5,065.83

About

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company's nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA under phase 2 stage for the treatment of SARS-CoV-2; GLS-5100 under pre-clinical stage for prevention of herpes zoster; and GLS-5140 under pre-clinical stage for the treatment of SFTS prophylaxis. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C re-infection prophylaxis, as well as GLS-6100 that is in pre-clinical stage for hepatitis C prophylaxis. Further, the company's discovery and optimization stage pipeline comprise GLS-7000 for the treatment of breast cancer; GLS-7100 for treating hemophilia A; GLS-8000 for the prevention of chronic hepatitis B; and GLS-8100 for treating rheumatoid arthritis. Additionally, it engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Young-Keun Park J.D., M.B.A.
  • Employees41
  • HeadquartersParc.1 NH Finance Tower, Seoul, South Korea, 07335, Korea
  • Websitehttps://www.genels.com

Leadership

  • Mr. Young-Keun Park J.D., M.B.A.CEO & Director · b. 1964
  • Mr. Byung-Mun Cho B.A., M.B.A.Executive VP & Executive Director · b. 1960
  • Jaekyung Chae B.A.Director of Finance & Accounting Division
  • Joel N. Maslow M.B.A., M.D., Ph.D.Chief Medical Officer

Financials

Income Statement

Currency: KRW2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue10.09B13.97B15.00B23.28B27.74B19.41B20.66B24.63B28.36B31.37B27.17B34.29B41.24B41.50B38.70B48.72B40.20B35.72B23.93B
Growth (%)-+38.49%+7.37%+55.17%+19.14%-30.02%+6.42%+19.21%+15.19%+10.60%-13.39%+26.21%+20.26%+0.63%-6.75%+25.89%-17.48%-11.15%-33.00%
Cost of Revenue8.72B12.71B14.26B17.42B23.29B17.44B16.48B20.62B20.72B23.27B21.52B23.60B28.35B30.09B29.94B39.38B47.96B46.59B45.36B
Gross Profit1.37B1.27B748.83M5.86B4.44B1.97B4.17B4.00B7.64B8.10B5.66B10.70B12.89B11.41B8.76B9.34B-7.76B-10.87B-21.43B
Gross Margin13.53%9.07%4.99%25.19%16.02%10.14%20.21%16.25%26.95%25.81%20.81%31.19%31.25%27.50%22.63%19.16%-19.30%-30.43%-89.53%
Operating Expense6.31B6.51B8.20B7.62B9.19B10.36B10.48B10.43B11.27B22.09B30.52B21.96B21.10B29.87B36.26B49.42B40.61B32.17B21.00B
Operating Income-4.94B-5.24B-7.45B-1.76B-4.75B-8.40B-6.31B-6.43B-3.63B-13.99B-24.86B-11.26B-8.21B-18.46B-27.51B-40.08B-48.37B-43.04B-42.42B
Operating Margin-48.96%-37.53%-49.64%-7.56%-17.11%-43.26%-30.55%-26.10%-12.79%-44.61%-91.50%-32.83%-19.90%-44.48%-71.08%-82.27%-120.31%-120.49%-177.27%
EBITDA-2.47B-5.13B-5.45B-4.37B-2.17B-5.75B-5.61B-4.58B-2.50B-12.03B-20.34B-9.05B-1.82B-13.64B-6.54B-25.32B-63.70B-28.64B-28.60B
EBITDA Margin-24.45%-36.70%-36.29%-18.79%-7.82%-29.60%-27.17%-18.61%-8.82%-38.34%-74.84%-26.39%-4.42%-32.86%-16.90%-51.97%-158.44%-80.17%-119.51%
Net Income-2.90B-5.85B-8.42B-7.59B-4.94B-8.89B-8.36B-6.49B1.41B-15.60B-23.73B-11.90B-7.62B-18.65B-15.95B-38.15B-77.77B-48.54B-47.66B
Net Income Margin-28.77%-41.86%-56.09%-32.61%-17.80%-45.79%-40.48%-26.36%4.98%-49.72%-87.33%-34.69%-18.47%-44.93%-41.22%-78.31%-193.44%-135.88%-199.16%
R&D14.44M1.04M5.67M19.43M697.58M2.07B2.39B759.49M830.85M3.93B8.40B5.66B5.87B8.40B11.44B12.15B7.04B3.56B1.93B
R&D as % of Total Revenue0.14%0.01%0.04%0.08%2.51%10.66%11.58%3.08%2.93%12.53%30.91%16.51%14.24%20.23%29.56%24.93%17.52%9.96%8.06%
Interest Expense214.83M426.17M556.63M847.18M219.82M1.17B820.50M144.11M43.72M1.24B1.84B1.39B1.97B628.50M4.45B7.31B1.18B2.16B2.37B
Interest Expense % of Total Revenue2.13%3.05%3.71%3.64%0.79%6.04%3.97%0.59%0.15%3.95%6.78%4.06%4.77%1.51%11.51%15.00%2.93%6.04%9.92%

Balance Sheet

Currency: KRW2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets43.33B38.43B59.04B40.05B40.46B39.96B31.82B40.77B47.69B65.66B45.63B49.30B51.15B136.57B249.50B222.87B151.01B151.33B119.21B
Total Liabilities7.99B8.95B19.30B8.02B6.67B13.22B8.11B6.03B8.25B29.81B9.09B19.89B27.09B38.06B44.04B41.40B39.52B65.73B78.31B
Total Equity35.34B29.48B39.74B32.04B33.79B26.74B23.71B34.73B39.44B35.85B36.54B29.41B24.06B98.51B206.51B181.47B111.49B85.61B40.90B
Cash22.03B1.68B4.09B3.38B3.22B2.99B5.85B7.26B9.69B20.76B12.02B8.38B16.92B62.43B22.31B13.26B9.11B1.18B1.34B
Total Debt7.24B2.46B10.33B2.46B3.25B10.57B2.71B816.13M1.17B22.07B1.46B12.39B14.49B17.77B18.40B19.67B17.16B27.13B32.96B
Net Debt-14.79B780.80M6.24B-922.84M30.51M7.57B-3.15B-6.44B-8.53B1.30B-10.56B4.01B-2.43B-44.67B-3.91B6.40B8.05B25.95B31.62B

Cash Flow

Currency: KRW2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.27B-3.15B-3.04B-3.88B-2.87B-6.20B-2.35B-4.16B778.50M-12.39B-4.04B-7.27B-1.27B-15.92B-4.85B-24.11B-21.74B-16.06B-16.52B
Investing Cash Flow-3.84B-10.55B-19.16B13.06B-5.06B-2.66B9.92B-9.62B-897.65M-2.16B-388.63M-8.01B10.47B-44.31B-146.40B8.06B25.89B-2.85B-769.89M
Financing Cash Flow3.77B-6.65B24.02B-10.00B7.16B8.67B-4.67B15.18B2.48B25.19B-3.96B11.61B-657.00M106.23B111.02B7.01B-8.29B10.96B17.45B
Capital Expenditure3.26B2.10B1.33B4.29B344.62M162.98M224.55M740.36M2.12B2.13B412.60M3.64B3.01B16.37B82.52B45.41B5.65B3.37B23.82M
Free Cash Flow-6.53B-5.25B-4.37B-8.17B-3.22B-6.37B-2.57B-4.90B-1.35B-14.52B-4.45B-10.91B-4.28B-32.29B-87.37B-69.52B-27.40B-19.42B-16.55B
FCF to OCF199.61%166.79%143.74%210.64%111.99%102.63%109.57%117.80%-172.85%117.20%110.21%150.11%336.97%202.85%1801.68%288.31%126.00%120.97%100.14%

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Sep 30, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------------------------------------------------------------
EPS Actual-27.22-273.28-121.41-113.41-20.16-65.21-5.83-45.50-40.51-46.15-156.45-144.52-117.40-74.06-21.31-14.02-53.80-39.02-125.62-129.37-141.21542.60-56.44-186.58-794.79-717.21-693.91-768.10-1215.29-596.23-912.82-382.35-391.78-368.69-367.08-19.57-169.15-48.81-381.77-209.20-359.89-246.49-698.31-133.78-455.47-398.55-151.17-298.56-708.25-509.77-944.68-851.93-850.97-744.26-2542.74-605.28-802.05-664.12-980.04-553.51-931.96-675.79-946.95-137.15-1044.90
Surprise-----------------------------------------------------------------
Timing-----------------------------------------------------------------

Key Statistics & Ratios

Market Cap9.71B
Enterprise Value77.60B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales0.79
Price / Book1.36
Revenue (TTM)12.37B
Gross Profit (TTM)-16.92B
EBITDA-24.87B
Profit Margin0.00%
Operating Margin-722.76%
Return on Equity-99.68%
Return on Assets-20.90%
Shares Outstanding18.18M
Shares Float16.49M
Beta0.72
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20031×
26.14Dec 29, 2003
20021×
39.21Dec 27, 2002
20012×
39.21Dec 27, 200139.21Jan 2, 2001
20001×
39.21Jan 4, 2000
19991×
9.80Jan 4, 1999

Stock Splits

  • Jun 25, 20260.2:1
  • Dec 3, 20211.5:1
  • Jan 16, 20151:5
  • Jul 6, 20065:1
  • Feb 6, 20065:1